Lidiya Bebrevska

Clinical PK characterization of EGT710, a novel coronavirus Mpro inhibitor, and simulation of target attainment rates for efficacious dose prediction

S. Ghanshani, Suzanne Gaudet, Lidiya Bebrevska, Jonathan Trolander +9 more

2026Clinical PK characterization of EGT710, a novel coronavirus Mpro inhibitor, and simulation of target attainment rates for efficacious dose prediction0 citations Open access

Semantic Scholar

Lidiya Bebrevska

Most-cited papers

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

In vivo antioxidative activity of a quantified Pueraria lobata root extract.

Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

Development and Validation of an HPLC Method for Quality Control of Pueraria lobata Flower

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development

Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites

An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2.

Optimization and Validation of an HPLC–Method for Quality Control of Pueraria Lobata Root

Relative Bioavailability and Food Effect of Asciminib Pediatric Mini‐tablet Formulation Compared to the Reference Tablet Formulation in Healthy Adult Participants

Development and validation of an HPLC – method for quality control of Pueraria lobata Willd. flower plant material

A First in Human Study of VOB560 in Combination with MIK665 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, or Multiple Myeloma

Drug–drug interactions of icenticaftor (QBW251) with a 5‐probe cytochrome P450 cocktail and oral contraceptives

Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor

Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Concentration‐QTcF Modeling of Icenticaftor from a Randomized, Placebo‐ and Positive‐Controlled Thorough QT Study in Healthy Participants

In vivo antioxidative activivty of a Pueraria lobata root extract in a diabetic rat model

Clinical PK characterization of EGT710, a novel coronavirus Mpro inhibitor, and simulation of target attainment rates for efficacious dose prediction

Chemopreventive principles from Pueararia lobata flowers: In Vitro Evaluation of the Inhibition of the NF kappa B activating signaling pathway